TLDR
- Kenvue delivered Q1 adjusted earnings of $0.32 per share, surpassing analyst expectations of $0.26–$0.31
- Quarterly revenue reached $3.91 billion, representing a 4.5% year-over-year increase and exceeding the $3.84 billion forecast
- The Skin Health and Beauty division drove performance with an impressive 8.4% revenue jump
- Kimberly-Clark’s $40 billion takeover remains scheduled for completion in H2 2026
- Forward guidance was withheld by the company due to the ongoing merger transaction
Kenvue (KVUE) delivered first-quarter financial results on Thursday that exceeded analyst projections for both earnings and revenue, sending shares higher by approximately 1.78% during trading.
The consumer healthcare giant announced adjusted earnings of $0.32 per share, comfortably beating the consensus analyst forecast ranging from $0.26 to $0.31. Quarterly revenue totaled $3.91 billion for the period concluding March 29, marking a 4.5% increase from the prior year’s $3.74 billion and surpassing the anticipated $3.84 billion.
Organic revenue advanced 0.7%, fueled by 1.0% positive pricing momentum, though partially dampened by a 0.3% decrease in volume.
KVUE shares had dipped 0.11% during pre-market activity before the earnings release, but the strong performance helped restore investor confidence.
Chief Executive Officer Kirk Perry highlighted that the organization achieved consecutive quarters of net and organic revenue growth, accompanied by year-over-year enhancements in gross margin, operating margin, and earnings per share.
Adjusted gross profit margin widened by 80 basis points to 60.8%, driven by supply chain efficiency improvements and beneficial pricing strategies that successfully countered inflationary pressures and tariff-related challenges. Adjusted operating income margin climbed to 24.0% compared to 19.8% in the corresponding period last year.
Skin Health and Beauty Leads the Way
The Skin Health and Beauty division emerged as the top performer, posting net revenue growth of 8.4% to reach $1.06 billion. Popular brands including Neutrogena and Aveeno fueled global consumer demand.
Self Care increased 1.9% while Essential Health advanced 4.9%. The Self Care segment faced headwinds from a subdued cold and flu season throughout key international markets.
Management indicated that its ongoing restructuring initiative is projected to generate pre-tax charges of approximately $250 million throughout the current fiscal year.
Kimberly-Clark Deal Shapes the Outlook
Kenvue opted not to provide forward-looking guidance given the pending $40 billion merger with Kimberly-Clark, which remains on schedule for completion during the second half of 2026, pending international regulatory clearances.
Kimberly-Clark shares advanced roughly 2.05% on the session, with market participants viewing Kenvue’s strong quarterly performance as positive for the acquiring company.
RBC Capital Markets analyst Nik Modi characterized the results as encouraging for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He observed that near-term stock movements will probably be influenced more significantly by merger timing developments and litigation news than by core operational performance.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
